Diethelm A G, Aldrete J S, Shaw J F, Cobbs C G, Hartley M W, Sterling W A, Morgan J M
Ann Surg. 1974 Jul;180(1):20-8. doi: 10.1097/00000658-197407000-00004.
Equine antithymocyte globulin combined with azathioprine and prednisone as immunosuppressive therapy in 50 transplant recipients prolonged allograft survival and seemed to modify the severity of rejection episodes. Although nine patients died from a variety of causes, only three kidneys were lost to rejection, one of which was hyperacute. There were no serious untoward hematologic or systemic effects caused by the ATG, and all patients completed the course of therapy. Infection, a serious and frequent complication of transplant patients, was encountered no more often than in other transplant series not using ALG. The data pertaining to the clinical value of ATG, although suggestive in terms of its immunosuppressive effects, is still not conclusive; and a definitive answer to this question awaits further evaluation in a series of cadaveric recipients in a randomized-double-blind study.
马抗胸腺细胞球蛋白联合硫唑嘌呤和泼尼松作为免疫抑制疗法应用于50例移植受者，可延长同种异体移植物存活时间，并似乎可减轻排斥反应的严重程度。尽管有9例患者死于各种原因，但只有3个肾脏因排斥反应而丢失，其中1例为超急性排斥反应。马抗胸腺细胞球蛋白未引起严重的不良血液学或全身影响，所有患者均完成了治疗疗程。感染是移植患者严重且常见的并发症，其发生率并不高于未使用抗淋巴细胞球蛋白的其他移植系列。关于马抗胸腺细胞球蛋白临床价值的数据，尽管在其免疫抑制作用方面具有提示性，但仍不具有决定性；对于这个问题的明确答案有待在一系列尸体供肾受者的随机双盲研究中作进一步评估。
